Study to evaluate clinical effects of Polymyxins and Ceftazidime-Avibactum in critical patients and evaluate which group has better outcomes (CoP CAcRE)
Not Applicable
- Conditions
- Health Condition 1: R652- Severe sepsis
- Registration Number
- CTRI/2023/10/058761
- Lead Sponsor
- Research institution
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Critically ill patients admitted in ICU with features of Sepsis
2.Microbiological culture confirmed CRE infection (Pulmonary and Blood stream)
3.Patients who have received CAZ/AVI or Polymyxins for at least 72 hours
Exclusion Criteria
1.Polymicrobial cultures
2.Patients who have already received CAZ/AVI or Polymyxins before ICU admission
3.Patients with CKD
4.Patients with chemotherapy or immunosuppressant therapy in last three months
•Post organ transplant patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method